

# **Personalized Medicine**

## **Part I: Scientific & Commercial Aspects**

**by**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**September 2017**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech.

Prof. Jain's 470 publications include 28 books (5 as editor + 23 as author) and 50 special reports which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. He has also written "The Textbook of Gene Therapy", which is the first book on this subject to be translated into the Chinese language in 2000. A book on gene therapy companies was published in 2000 by John Wiley & Sons and the updated version of it is incorporated in the 2013 edition of Gene Therapy published by Jain PharmaBiotech. The most recent books include "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011, 2<sup>nd</sup> ed Springer 2012, 3<sup>rd</sup> ed April 2017), "Textbook of Personalized Medicine" (Springer 2009, Japanese ed 2012; 2<sup>nd</sup> ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2<sup>nd</sup> ed Springer 2017), "Handbook of Neuroprotection" (Springer 2011), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Applied Neurogenomics" (Springer 2015).

Prof. Jain has been interested in using biotechnology to develop personalized medicine since 1997. He has also lectured and conducted several workshops on personalized medicine worldwide.

## **A B O U T   T H I S   R E P O R T**

Prof. Jain wrote the first report on Personalized Medicine in 1998, which was published by Decision Resources Inc, USA. The second edition was published in 2001 by Informa Publications, London. Since 2003, the report is published and continuously updated and rewritten at Jain PharmaBiotech.

**September 2017 (first edition published in 1998 by Decision Resources Inc)  
Copyright © 2017 by**

**Jain PharmaBiotech  
Bläsiring 7  
CH-4057 Basel  
Switzerland**

**Tel & Fax:    +4161-6924461  
Email:        info@pharmabiotech.ch  
Web site:     http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>25</b>
<b>1. Basic Aspects.....</b>	<b>27</b>
<b>Definition of personalized medicine.....</b>	<b>27</b>
<b>History of medical concepts relevant to personalized medicine .....</b>	<b>28</b>
Ayurveda as a personalized healthcare system .....	30
Personalized aspects of ancient oriental systems of medicine .....	30
Evolution of modern personalized medicine .....	30
<b>Molecular biological basis of personalized medicine .....</b>	<b>31</b>
The human genome .....	31
<i>ENCODE</i> .....	31
Chromosomes .....	32
Genes.....	32
<i>The genetic code</i> .....	33
<i>Gene expression</i> .....	33
<i>DNA sequences and structure</i> .....	33
Genetic variations in the human genome .....	34
<i>Single nucleotide polymorphisms</i> .....	34
<i>Copy number variations in the human genome</i> .....	35
<i>Insertions and deletions in the human genome</i> .....	36
<i>Large scale variation in human genome</i> .....	37
<i>Structural variations in the human genome</i> .....	38
<i>Mapping and sequencing of structural variation from human genomes</i> .....	38
<i>1000 Genomes Project</i> .....	39
<i>Role of DNA sequencing in the development of personalized medicine</i> .....	40
<i>Human Variome Project</i> .....	41
<i>Interconnected genetic and genomic patterns in human diseases</i> .....	41
Mitochondrial tRNA and personalized medicine.....	42
<b>Basics technologies for developing personalized medicine .....</b>	<b>42</b>
Definitions of technologies relevant to personalized medicine .....	42
Problems with the ICH definitions of pharmacogenomics and pharmacogenetics .....	43
<b>'Omics' and personalized medicine .....</b>	<b>43</b>
Relationship of various technologies to personalized medicine .....	44
<b>Conventional medicine versus personalized medicine .....</b>	<b>44</b>
<b>Personalized medicine and evidence-based medicine .....</b>	<b>45</b>
<b>Role of genetics in future approaches to healthcare .....</b>	<b>45</b>
Genetic medicine .....	45
Human disease and genes.....	46
Genetic and environmental interactions in etiology of human diseases.....	46
Role of genetics in development of personalized medicines .....	47
<i>Genetic databases</i> .....	47
<i>Clinical Genomic Database</i> .....	47
<i>Genetic epidemiology</i> .....	48
<i>Limitations of medical genetics</i> .....	48
<i>Genetics vs. epigenetics</i> .....	49
<b>Role of systems biology in personalized medicine .....</b>	<b>49</b>
Systems pharmacology.....	50
Systems medicine .....	51
<b>Synthetic biology and development of personalized medicines.....</b>	<b>52</b>
<b>Role of bioelectronics in development of personalized medicine .....</b>	<b>53</b>
<b>A personalized approach to environmental factors in disease.....</b>	<b>53</b>
<b>Reclassification of diseases .....</b>	<b>53</b>
<b>Translational science and personalized medicine.....</b>	<b>54</b>
<b>Personalization of multimodal therapies.....</b>	<b>55</b>
<b>2. Molecular Diagnostics in Personalized Medicine .....</b>	<b>57</b>
<b>Introduction .....</b>	<b>57</b>
<b>Molecular diagnostic technologies .....</b>	<b>57</b>
PCR-based methods .....	58
<i>DirectLinear™ Analysis</i> .....	58
<i>Denaturing high-performance liquid chromatography</i> .....	59
<i>Multiplex Allele-Specific Diagnostic Assay</i> .....	59
<i>Representational oligonucleotide microarray analysis</i> .....	59
<i>Restriction fragment length polymorphism (RFLP)</i> .....	59
<i>Real-time PCR for detection of CNVs</i> .....	60
Non-PCR methods.....	60
<i>Arrayed primer extension (APEX)</i> .....	60
<i>Enzymatic Mutation Detection (EMD)</i> .....	60

DNA sequencing .....	60
<i>Sanger-sequencing technology</i> .....	61
<i>ABI PRISM® 310 Genetic Analyzer</i> .....	62
<i>High-throughput paired end transcriptome sequencing</i> .....	62
Emerging sequencing technologies.....	62
<i>4300 DNA analyzer</i> .....	63
<i>Apollo 100</i> .....	63
<i>"Color blind" approach to DNA sequencing</i> .....	64
<i>Cyclic array sequencing</i> .....	64
<i>CEQ™ 8000</i> .....	64
<i>DeepCAGE sequencing</i> .....	64
<i>Electron microscope-based DNA sequencing</i> .....	65
<i>Genometrica™ sequencer</i> .....	65
<i>GS-FLEX system (Roche/454)</i> .....	66
<i>IBS sequencing technology</i> .....	67
<i>Illumina's sequencing technology</i> .....	67
<i>MegaBACE 500</i> .....	68
<i>Microdroplet-based PCR for large-scale targeted sequencing</i> .....	68
<i>Multiplex amplification of human DNA sequences</i> .....	69
<i>Nanoscale sequencing</i> .....	69
<i>Polonator sequencer</i> .....	69
<i>RainStorm™ microdroplet technology</i> .....	70
<i>Sequential DEXAS</i> .....	70
<i>SOLiD technology</i> .....	71
<i>Sequencing by hybridization</i> .....	72
<i>Whole genome sequencing</i> .....	72
<i>Bioinformatic tools for analysis of genomic sequencing data</i> .....	73
<i>Clinical Genomicist Workspace for managing NGS-based clinical tests</i> .....	73
<i>Detection of single molecules in real time</i> .....	73
<i>Direct observation of nucleotide incorporation</i> .....	73
<i>Molecular Combing</i> .....	74
<i>Nanopore sequencing</i> .....	74
<i>DNA sequence by use of nanoparticles</i> .....	74
<i>Zero-mode waveguide nanostructure arrays</i> .....	74
<i>Future prospects of sequencing</i> .....	75
<i>Role of DNA sequencing in development of personalized medicine</i> .....	75
<i>Role of RNA sequencing in development of personalized medicine</i> .....	77
<b>Biochips and microarrays</b> .....	<b>77</b>
Role of biochip/microarray technology in personalized medicine.....	78
Applications of biochip/microarray technology in personalized medicine .....	79
Standardizing the microarrays .....	80
Biochip technologies.....	80
<i>GeneChip</i> .....	80
<i>AmpliChip CYP450</i> .....	81
Microfluidics .....	82
<i>Lab-on-a-chip</i> .....	83
<i>Micronics' microfluidic technology</i> .....	83
<i>LabCD</i> .....	83
<i>Microfluidic automated DNA analysis using PCR</i> .....	83
<i>Integrated microfluidic bioassay chip</i> .....	84
Electronic detection of nucleic acids on microarrays.....	84
Strand displacement amplification on a biochip .....	85
Rolling circle amplification on DNA microarrays.....	85
Universal DNA microarray combining PCR and ligase detection reaction .....	85
Protein biochips .....	85
<i>ProteinChip</i> .....	86
<i>LabChip for protein analysis</i> .....	87
<i>TRINECTIN proteome chip</i> .....	87
<i>Protein expression microarrays</i> .....	87
<i>Microfluidic devices for proteomics-based diagnostics</i> .....	88
<i>New developments in protein biochips/microarrays</i> .....	88
<i>Protein biochips/microarrays for personalized medicine</i> .....	89
<b>SNP genotyping</b> .....	<b>89</b>
Genotyping and haplotyping.....	90
<i>Haplotype Specific Extraction</i> .....	91
<i>Computation of haplotypes</i> .....	91
<i>HapMap project</i> .....	91
<i>Haplotyping for whole genome sequencing</i> .....	92
<i>Predicting drug response with HapMap</i> .....	94
<i>Companies developing haplotyping technology</i> .....	94
Technologies for SNP analysis.....	94

Biochip and microarray-based detection of SNPs .....	95
<i>SNP genotyping by MassARRAY</i> .....	95
<i>BeadArray technology</i> .....	95
<i>SNP-IT primer-extension technology</i> .....	96
<i>Use of NanoChip for detection of SNPs</i> .....	96
Electrochemical DNA probes .....	96
Laboratory Multiple Analyte Profile .....	96
PCR-CTPP (confronting two-pair primers).....	97
TaqMan real-time PCR .....	97
Locked nucleic acid .....	98
Molecular inversion probe based assays.....	98
Pyrosequencing .....	98
Smart amplification process version 2 .....	99
Zinc finger proteins .....	99
Mitochondrial SNPs.....	99
Limitations of SNP in genetic testing.....	100
Concluding remarks on SNP genotyping.....	100
Companies involved in developing technologies/products for SNP analysis .....	100
Impact of SNPs on personalized medicine .....	102
<b>Detection of copy number variations .....</b>	<b>102</b>
CNVer algorithm for CNV detection.....	102
CNVnator for discovery of CNVs and genotyping .....	103
<b>Study of rare variants in pinpointing disease-causing genes .....</b>	<b>103</b>
<b>Optical Mapping .....</b>	<b>104</b>
<b>Proteomics in molecular diagnosis.....</b>	<b>104</b>
Proteomic strategies for biomarker identification.....	105
<i>Proteomic technologies for detection of biomarkers in body fluids</i> .....	105
Protein patterns.....	105
Layered Gene Scanning .....	106
Comparison of proteomic and genomic approaches in personalized medicine.....	106
<b>Role of nanobiotechnology in molecular diagnostics.....</b>	<b>107</b>
Cantilevers for personalized medical diagnostics .....	107
<b>Role of biomarkers in personalized medicine.....</b>	<b>108</b>
<b>Role of biosensors in personalized medicine.....</b>	<b>110</b>
Biomarkers for diagnostics .....	111
Biomarkers for drug development .....	111
<b>Gene expression profiling .....</b>	<b>111</b>
DNA microarrays.....	112
Analysis of single-cell gene expression.....	112
Gene expression profiling based on alternative RNA splicing .....	113
Whole genome expression array .....	114
Tangerine™ expression profiling .....	114
Gene expression analysis on biopsy samples .....	115
Profiling gene expression patterns of white blood cells.....	115
Serial analysis of gene expression (SAGE).....	115
Multiplexed Molecular Profiling .....	116
Gene expression analysis using competitive PCR and MALDI TOF MS .....	116
Companies involved in gene expression analysis .....	117
Monitoring in vivo gene expression by molecular imaging .....	118
<b>Molecular imaging and personalized medicine.....</b>	<b>118</b>
<b>Combination of diagnostics and therapeutics .....</b>	<b>118</b>
Use of molecular diagnostics for stratification in clinical trials .....	119
Companion diagnostics .....	119
Companies involved in companion diagnostics .....	120
<b>Point-of-care diagnosis.....</b>	<b>122</b>
Companies developing point-of-care diagnostic technologies .....	123
Point-of-care diagnosis of infections .....	125
Advantages versus disadvantages of point-of-care diagnosis .....	125
Future prospects of point-of-care diagnosis .....	126
<b>Genetic testing for disease predisposition .....</b>	<b>126</b>
Preventive genetics by early diagnosis of mitochondrial diseases .....	127
Direct-to-consumer genetic services.....	127
<b>Role of diagnostics in integrated healthcare .....</b>	<b>128</b>
Concept of integrated healthcare .....	128
Components of integrated healthcare .....	129
<i>Screening</i> .....	129
<i>Disease prediction</i> .....	129
<i>Early diagnosis</i> .....	129
<i>Prevention</i> .....	130
<i>Therapy based on molecular diagnosis</i> .....	130
<i>Monitoring of therapy</i> .....	130

Advantages and limitations of integrated healthcare.....	130
Commercially available systems for integrated healthcare.....	131
<b>Future of molecular diagnostics in personalized medicine .....</b>	<b>131</b>

<b>3. Pharmacogenetics .....</b>	<b>133</b>
<b>Basics of pharmacogenetics.....</b>	<b>133</b>
<b>Role of molecular diagnostics in pharmacogenetics.....</b>	<b>134</b>
<b>Role of pharmacogenetics in pharmaceutical industry.....</b>	<b>135</b>
Study of the drug metabolism and pharmacological effects .....	135
Causes of variations in drug metabolism .....	135
Enzymes relevant to drug metabolism .....	136
Pharmacogenetics of phase I metabolism.....	136
<i>CYP450</i> .....	136
<i>P450 CYP 2D6 inhibition by selective serotonin reuptake inhibitors</i> .....	138
<i>Cytochrome P450 polymorphisms and response to clopidogrel</i> .....	139
<i>Lansoprazole and cytochrome P450</i> .....	139
<i>Glucose-6-phosphate dehydrogenase</i> .....	139
Pharmacogenetics of phase II metabolism.....	140
<i>N-Acetyltransferase</i> .....	140
<i>Uridine diphosphate-glucuronosyltransferase</i> .....	141
Measurement of CYP isoforms .....	141
Polymorphism of drug transporters .....	142
Genetic variation in drug targets.....	142
<i>Polymorphisms of kinase genes</i> .....	143
Effect of genetic polymorphisms on disease response to drugs .....	143
Ethnic differences in drug metabolism .....	144
Gender differences in pharmacogenetics .....	144
Role of pharmacogenetics in drug safety .....	145
<i>Adverse drug reactions</i> .....	145
<i>Adverse drug reactions in children</i> .....	146
<i>Adverse drug reactions related to toxicity of chemotherapy</i> .....	146
<i>Genetically determined adverse drug reactions</i> .....	146
<i>Malignant hyperthermia</i> .....	148
<i>Pharmacogenetics of clozapine-induced agranulocytosis</i> .....	148
<i>Role of pharmacogenetics in warfarin therapy</i> .....	149
<i>Role of pharmacogenetics in antiplatelet therapy</i> .....	150
<i>Role of pharmacogenetics in carbamazepine therapy</i> .....	151
<i>Role of pharmacogenetics in statin therapy</i> .....	151
<i>FDA consortium linking genetic biomarkers to serious adverse events</i> .....	152
Therapeutic drug monitoring, phenotyping, and genotyping .....	153
<i>Therapeutic drug monitoring</i> .....	153
<i>Phenotyping</i> .....	154
<i>Genotyping</i> .....	155
<i>Genotyping vs phenotyping</i> .....	155
Phenomics .....	156
<i>Limitations of genotype-phenotype association studies</i> .....	156
Molecular toxicology in relation to personalized medicines.....	156
<i>Toxicogenomics</i> .....	157
<i>Biomarkers of drug toxicity</i> .....	157
<i>Drug-induced mitochondrial toxicity</i> .....	157
<i>Companies involved in molecular toxicology</i> .....	158
<i>Gene expression studies</i> .....	158
Pharmacogenetics in clinical trials .....	159
Postmarketing pharmacogenetics.....	159
<b>Clinical implications of pharmacogenetics .....</b>	<b>160</b>
<i>Application of CYP450 genotyping in clinical practice</i> .....	160
<i>Genotype-based drug dose adjustment</i> .....	160
<i>Pharmacogenomic biomarker information in drug labels</i> .....	160
<i>Standardized terminology for clinical pharmacogenetic test results</i> .....	164
Use of pharmacogenetics in clinical pharmacology.....	164
<i>Application of CYP2C19 pharmacogenetics for personalized medicine</i> .....	164
<i>Genotyping for identifying responders to sulfasalazine</i> .....	164
<i>HLA alleles associated with lumiracoxib-related liver injury</i> .....	165
<i>Pharmacogenetic basis of thiopurine toxicity</i> .....	165
<i>Tranilast-induced hyperbilirubinemia due to gene polymorphism</i> .....	166
Linking pharmacogenetics with pharmacovigilance .....	166
<i>Genetic susceptibility to ADRs</i> .....	166
<i>Linking genetic testing to postmarketing ADR surveillance</i> .....	166
<i>Recommendations for the clinical use of pharmacogenetics</i> .....	167
<b>Limitations of pharmacogenetics .....</b>	<b>167</b>
<b>Pharmacoepigonomics vs pharmacogenetics in drug safety .....</b>	<b>168</b>

<b>Future role of pharmacogenetics in personalized medicine .....</b>	<b>168</b>
<b>4. Pharmacogenomics.....</b>	<b>169</b>
<b>Introduction .....</b>	<b>169</b>
<b>Basics of pharmacogenomics .....</b>	<b>170</b>
<b>Pharmacogenomics and drug discovery .....</b>	<b>170</b>
<i>Preclinical prediction of drug efficacy .....</i>	<i>172</i>
<b>Pharmacogenomics and clinical trials .....</b>	<b>172</b>
Impact of genetic profiling on clinical studies .....	173
Limitations of the pharmacogenomic-based clinical trials.....	174
<b>Pharmacogenomic aspects of major therapeutic areas .....</b>	<b>175</b>
Oncogenomics .....	175
<i>Oncogenes.....</i>	<i>175</i>
<i>Tumor suppressor genes.....</i>	<i>176</i>
Cardiogenomics .....	177
Neuropharmacogenomics.....	179
<i>Pharmacogenomics of Alzheimer's disease .....</i>	<i>179</i>
<i>Pharmacogenomics of depression.....</i>	<i>180</i>
<i>Pharmacogenomics of schizophrenia.....</i>	<i>180</i>
<i>Companies involved in neurogenomics-based drug discovery.....</i>	<i>181</i>
<b>Current status and future prospects of pharmacogenomics .....</b>	<b>181</b>
<b>5. Role of Pharmacoproteomics .....</b>	<b>183</b>
<b>Basics of proteomics .....</b>	<b>183</b>
<b>Proteomic approaches to the study of pathophysiology of diseases .....</b>	<b>184</b>
Single cell proteomics for personalized medicine .....	184
Diseases due to misfolding of proteins .....	184
<i>Therapies for protein misfolding.....</i>	<i>185</i>
Significance of mitochondrial proteome in human disease .....	186
<b>Proteomic technologies for drug discovery and development .....</b>	<b>186</b>
Proteins and drug action .....	186
Role of reverse-phase protein microarray in drug discovery.....	186
Role of proteomics in clinical drug safety.....	187
Toxicoproteomics .....	187
<b>Applications of pharmacoproteomics in personalized medicine .....</b>	<b>188</b>
<b>6. Role of Metabolomics in Personalized Medicine .....</b>	<b>189</b>
<b>Metabolomics and metabonomics .....</b>	<b>189</b>
<b>Metabolomics bridges the gap between genotype and phenotype .....</b>	<b>189</b>
<b>Metabolomics, biomarkers and personalized medicine .....</b>	<b>190</b>
<b>Metabolomic technologies .....</b>	<b>190</b>
Urinary profiling by capillary electrophoresis.....	191
Lipid profiling .....	191
Role of metabolomics in biomarker identification and pattern recognition.....	192
Validation of biomarkers in large-scale human metabolomics studies.....	192
<b>Pharmacometabonomics.....</b>	<b>193</b>
<b>Metabonomic technologies for toxicology studies.....</b>	<b>193</b>
<b>Metabonomics/metabolomics and personalized nutrition.....</b>	<b>194</b>
<b>7. Personalized Biological Therapies.....</b>	<b>195</b>
<b>Introduction .....</b>	<b>195</b>
<b>Recombinant human proteins .....</b>	<b>195</b>
<b>Therapeutic monoclonal antibodies .....</b>	<b>195</b>
<b>Cell therapy .....</b>	<b>196</b>
Autologous tissue and cell transplants .....	196
Stem cells.....	196
<i>iPSCs for personalized cell therapy .....</i>	<i>196</i>
<i>Role of stem cells derived from unfertilized embryos .....</i>	<i>197</i>
Cloning and personalized cell therapy .....	197
Use of stem cells for drug testing.....	197
<b>Gene therapy .....</b>	<b>197</b>
Gene editing by CRISPR/Cas9 system.....	198
Personalized gene therapy for cancer .....	198
<i>Stem cell-based personalized gene therapy for cancer .....</i>	<i>199</i>
<b>Personalized vaccines.....</b>	<b>199</b>
Personalized vaccines for viral diseases .....	199
Personalized cancer vaccines.....	199
<b>Antisense therapy.....</b>	<b>199</b>
RNA interference.....	200
MicroRNAs .....	201

<b>8. Personalized Non-pharmacological Therapies.....</b>	<b>203</b>
<b>Introduction .....</b>	<b>203</b>
<b>Acupuncture .....</b>	<b>203</b>
Personalized acupuncture therapy .....	203
<b>Personalized hyperbaric oxygen therapy .....</b>	<b>204</b>
<b>Personalized nutrition.....</b>	<b>204</b>
Nutrigenomics .....	205
<i>Evolutionary basis of nutrigenomics .....</i>	<i>205</i>
<i>Genomics of vitamin D and calcium supplementation.....</i>	<i>206</i>
<i>Nutrigenomics and functional foods.....</i>	<i>206</i>
<i>Nutrigenomics and personalized medicine .....</i>	<i>207</i>
<i>Nutriproteomics.....</i>	<i>207</i>
Nutrigenetics and personalized medicine.....	207
Personalized diet prescription .....	208
<i>Personalized nutrition and aging .....</i>	<i>209</i>
<i>Personalized diet for diabetics.....</i>	<i>209</i>
Role of systems medicine in personalized nutrition.....	209
Companies involved in personalized nutrition .....	209
<b>Personalized physical exercise .....</b>	<b>210</b>
Variations in response to aerobic exercise.....	210
Variations in exercise-induced muscle hypertrophy and strength.....	211
<b>Personalized surgery .....</b>	<b>211</b>
<b>9. Personalized Medicine in Major Therapeutic Areas .....</b>	<b>213</b>
<b>Introduction .....</b>	<b>213</b>
<b>Personalized management of infections .....</b>	<b>214</b>
Genetic susceptibility to infections.....	214
Management of HIV .....	214
<i>CD4 counts as a guide to drug therapy for AIDS .....</i>	<i>214</i>
<i>Drug-resistance in HIV .....</i>	<i>214</i>
<i>Genetics of human susceptibility to HIV infection .....</i>	<i>216</i>
<i>Measurement of Replication Capacity.....</i>	<i>216</i>
<i>Personalized vaccine for HIV.....</i>	<i>217</i>
<i>Prevention of adverse reactions to antiviral drugs .....</i>	<i>217</i>
<i>Pharmacogenetics and HIV drug safety.....</i>	<i>218</i>
<i>Pharmacogenomics of antiretroviral agents .....</i>	<i>218</i>
<i>Role of diagnostic testing in management of HIV .....</i>	<i>218</i>
<i>Role of genetic variations in susceptibility to HIV-1 .....</i>	<i>219</i>
<i>Role of personalized HIV therapy in controlling drug resistance.....</i>	<i>219</i>
<i>PhenoSense® to test HIV drug resistance.....</i>	<i>220</i>
<i>Sequencing for detecting mutations to personalize HIV therapy .....</i>	<i>220</i>
Personalized treatment of hepatitis B .....	221
Personalized treatment of hepatitis C .....	221
<i>Responders vs non-responders to treatment for hepatitis C.....</i>	<i>222</i>
<i>Drug resistance in hepatitis C.....</i>	<i>223</i>
Personalized management of tuberculosis .....	223
Personalized management of fungal infections.....	224
<b>Psychiatric disorders .....</b>	<b>224</b>
Psychopharmacogenetics/psychopharmacodynamics .....	225
<i>Serotonin genes.....</i>	<i>225</i>
<i>Calcium channel gene.....</i>	<i>225</i>
<i>Dopamine receptor genes .....</i>	<i>225</i>
<i>COMT genotype and response to amphetamine.....</i>	<i>225</i>
<i>Methylenetetrahydrofolate reductase.....</i>	<i>226</i>
<i>Genetic loci associated with risk of major depressive disorder.....</i>	<i>226</i>
<i>Role of gene mutations in ADHD .....</i>	<i>226</i>
<i>Genotype and response to methylphenidate in children with ADHD .....</i>	<i>227</i>
<i>GeneSight tests for individualized therapy of psychiatric disorders .....</i>	<i>227</i>
Personalized antipsychotic therapy.....	227
Personalized antidepressant therapy .....	229
<i>Biomarkers of response to antidepressant treatment.....</i>	<i>230</i>
<i>EEG to predict adverse effects and evaluate antidepressant efficacy.....</i>	<i>231</i>
<i>Individualization of SSRI treatment.....</i>	<i>231</i>
<i>Role of protein sFRP3 in predicting response to antidepressants.....</i>	<i>233</i>
<i>Treatment resistant depression.....</i>	<i>233</i>
<i>Vilazodone with a test for personalized treatment of depression.....</i>	<i>234</i>
<b>Neurological disorders .....</b>	<b>234</b>
Introduction to personalized neurology .....	234
Personalized management of Alzheimer's disease .....	235
Personalized management of Parkinson's disease.....	236
<i>Direct-to-consumer genetic testing in PD .....</i>	<i>236</i>



<i>Discovery of subgroup-selective drug targets in PD</i> .....	237
<i>Personalized cell therapy for PD</i> .....	237
Personalized management of amyotrophic lateral sclerosis .....	238
Personalized management of epilepsy .....	238
<i>Biomarkers of epilepsy</i> .....	238
<i>Genetics/genomics of epilepsy</i> .....	240
<i>Choice of the right AED</i> .....	240
<i>Adverse effects of AEDs</i> .....	241
<i>Pharmacogenomics of epilepsy</i> .....	241
<i>Drug resistance in epilepsy</i> .....	243
<i>An algorithm for personalized management of epilepsy</i> .....	244
<i>Future of management of epilepsy</i> .....	245
Personalized management of migraine .....	246
<i>Individualization of use of triptans for migraine</i> .....	246
<i>Multitarget therapeutics for personalized treatment of headache</i> .....	247
<i>Personalized strategy for prevention of migraine attacks</i> .....	247
Personalized management of intracranial aneurysms .....	248
<i>Personalized management of cerebral vasospasm following SAH</i> .....	248
Personalized management of stroke .....	248
<i>Anticoagulation for stroke prevention</i> .....	249
<i>Application of proteomics for personalizing stroke management</i> .....	250
<i>Brain imaging in trials of restorative therapies for stroke</i> .....	250
<i>Personalized management of intracerebral hemorrhage</i> .....	251
<i>Revascularization procedures in chronic post-stroke stage</i> .....	251
<i>Personalized cell therapy for management of stroke</i> .....	252
<i>Management of stroke according to stage</i> .....	252
Personalized treatment of multiple sclerosis .....	252
<i>Immunopathological patterns of demyelination for assessing therapy</i> .....	253
<i>Personalizing mitoxantrone therapy of multiple sclerosis</i> .....	254
<i>Autologous bone marrow stem cell therapy for multiple sclerosis</i> .....	254
<i>Fusokine method of personalized cell therapy of multiple sclerosis</i> .....	254
<i>Pharmacogenomics of IFN-<math>\beta</math> therapy in multiple sclerosis</i> .....	255
<i>T cell-based personalized vaccine for MS</i> .....	256
Personalized management of traumatic brain injury .....	256
<i>Biomarkers of TBI</i> .....	256
<i>Comparative effectiveness research for management of TBI</i> .....	257
<i>CT scores for prognosis and risk stratification of TBI</i> .....	257
Personalized management of myasthenia gravis .....	258
Personalized management of pain .....	258
<i>Genetic factors in response to pain</i> .....	258
<i>Genetic mutations with loss of pain</i> .....	259
<i>Genetic mutations and painful conditions</i> .....	259
<i>Pharmacogenetics/pharmacogenomics of pain</i> .....	260
<i>Personalized management of pain with opioids</i> .....	260
<i>Pharmacogenetics of NSAIDs</i> .....	261
<i>Mechanism-specific management of pain</i> .....	262
<i>Preoperative testing to tailor postoperative analgesic requirements</i> .....	262
<i>Personalized analgesics</i> .....	262
<i>Signature of pain on brain imaging</i> .....	263
<i>Concluding remarks on personalized management of pain</i> .....	263
Personalized management of sleep disorders .....	264
<i>Personalized therapy of insomnia</i> .....	264
Future of personalized neurology .....	264
<b>Personalized management of ophthalmic disorders</b> .....	<b>265</b>
Proteomics-based personalized management of uveitis .....	265
Combining cell and gene therapies for retinal disorders .....	265
<b>Cardiovascular disorders</b> .....	<b>265</b>
Role of diagnostics in personalized management of cardiovascular disease .....	266
<i>Cardiovascular disorders with a genetic component</i> .....	266
<i>Gene mutations associated with risk of coronary heart disease</i> .....	267
<i>Gene variant as a risk factor for sudden cardiac death</i> .....	268
<i>KIF6 gene test as a guide to management of heart disease</i> .....	269
<i>NGS sequencing for management of cardiovascular disorders</i> .....	269
Assessing patients with coronary heart disease .....	270
Assessing coronary artery disease for percutaneous coronary interventions .....	271
Companion diagnostics for therapy of cardiovascular disorders .....	272
Biomarkers and personalized management of cardiovascular disorders .....	272
Pharmacogenomics of cardiovascular disorders .....	273
Nanotechnology-based personalized therapy of cardiovascular diseases .....	273
Personalized management of chronic myocardial ischemia .....	274
<i>Management of chronic angina pectoris</i> .....	274

Personalized management of myocardial infarction .....	275
Management of heart failure .....	275
<i>β-blockers</i> .....	275
<i>Bucindolol</i> .....	275
<i>BiDil</i> .....	276
Management of atrial fibrillation.....	276
Management of hypertension .....	278
<i>Adjusting therapy of hypertension to fluctuations of blood pressure</i> .....	279
<i>Choice of drugs for hypertension</i> .....	279
<i>Control of blood pressure with vagal nerve stimulation</i> .....	279
<i>Correction of causes and risk factors of hypertension</i> .....	280
<i>Genes and hypertension</i> .....	280
<i>Improving management of HPN by targeting new pathways</i> .....	281
<i>Individualized therapy of HPN based on risk factors of heart disease</i> .....	281
<i>Personalized management of hypertensive patients with albuminuria</i> .....	282
<i>Personalized management of hypertension in the elderly</i> .....	282
<i>Personalized management of hypertension in women</i> .....	283
<i>Pharmacogenomics of diuretic drugs</i> .....	283
<i>Pharmacogenomics of ACE inhibitors</i> .....	283
<i>Prediction of antihypertensive activity of rostaduroxin</i> .....	284
<i>Role of pharmacogenetics in management of hypertension</i> .....	284
<i>Scheme for management of hypertension by personalized approach</i> .....	285
Personalized lipid-lowering therapies .....	285
<i>NIR spectroscopy of plaques to guide cholesterol-lowering therapy</i> .....	286
<i>Polymorphisms in genes involved in cholesterol metabolism</i> .....	286
<i>Role of eNOS gene polymorphisms</i> .....	287
<i>Prediction of response to statins</i> .....	287
<i>Personalized management of women with hyperlipidemia</i> .....	288
<i>Therapeutic alternatives in patients with statin intolerance</i> .....	288
<i>Treatment of familial hypercholesterolemia</i> .....	289
<i>PCSK9 inhibitors</i> .....	289
Thrombotic disorders.....	290
<i>Factor V Leiden mutation</i> .....	290
<i>Anticoagulant therapy</i> .....	290
<i>Antiplatelet therapy</i> .....	292
Personalized management of aortic aneurysms.....	292
Clinical trials of personalized therapy of cardiovascular diseases .....	293
Project euHeart for personalized management of heart disease .....	293
Modification of life style factors in management of cardiovascular disorders .....	294
Systems biology approach to personalized cardiology .....	294
Concluding remarks on personalized management of cardiovascular diseases.....	295
<b>Personalized management of pulmonary disorders .....</b>	<b>295</b>
Role of genetic ancestry in lung function .....	295
Targeted drug delivery for personalized management of pulmonary disorders .....	296
Personalized therapy of asthma .....	296
<i>Asthma phenotyping for improving therapeutic precision</i> .....	297
<i>Biomarkers for predicting response to corticosteroid therapy</i> .....	297
<i>Genetic polymorphism and response to β<sub>2</sub>-adrenergic agonists</i> .....	297
<i>Genotyping in asthma</i> .....	298
<i>IgE as guide to dosing of omalizumab for asthma</i> .....	298
<i>Lebrikizumab for personalised treatment of asthma</i> .....	299
Personalized management of chronic obstructive pulmonary disease .....	299
Personalized management of idiopathic pulmonary fibrosis.....	300
<b>Personalized management of skin disorders.....</b>	<b>301</b>
Genetic testing for personalized skin care .....	301
Management of hair loss based on genetic testing.....	301
<b>Personalized urology .....</b>	<b>302</b>
<b>Personalized approaches in immunology .....</b>	<b>302</b>
<i>Immunological tests in personalized medicine</i> .....	302
<i>Antibody profiles</i> .....	302
<i>Role of Mannose-binding lectin testing in personalized medicine</i> .....	303
Pharmacogenetics and pharmacogenomics of immunosuppressive agents .....	303
Personalized management of patients with lupus erythematosus.....	303
<b>Personalized therapy of rheumatoid arthritis .....</b>	<b>304</b>
Biomarkers for personalizing therapy of rheumatoid arthritis .....	304
DIATSTAT™ anti-cyclic citrullinated peptides in rheumatoid arthritis.....	305
Genetics and epigenetic aspects of rheumatoid arthritis .....	305
Personalization of COX-2 inhibitor therapy .....	306
Personalized biological therapy of RA.....	306
Personalization of infliximab therapy .....	306
Personalized therapy of RA guided by anti-citrullinated protein antibodies.....	307

Variations in the effectiveness of therapies for RA .....	307
<b>Personalized management of obesity .....</b>	<b>307</b>
Basics of obesity .....	307
Genetics of obesity as a basis for personalized management .....	308
Limitations of personalized approach to management of obesity .....	308
<b>Personalized management of diabetes .....</b>	<b>309</b>
<b>Management of genetic disorders .....</b>	<b>310</b>
Personalized treatment of cystic fibrosis .....	310
<b>Personalized management of gastrointestinal disorders .....</b>	<b>311</b>
Role of microbiome in personalized management of gastrointestinal disorders .....	311
Personalized therapy of inflammatory bowel disease .....	311
Personalized management of lactose intolerance.....	312
<b>Personalized approaches to improve organ transplantation .....</b>	<b>313</b>
Personalization of kidney transplantation .....	313
<i>Cell-based bioengineered kidney transplant.....</i>	<i>313</i>
Personalization of cardiac transplantation.....	314
<i>Cell-based regeneration of heart for personalized transplantation.....</i>	<i>314</i>
Prediction of rejection for personalizing anti-rejection treatment.....	315
Personalized immunosuppressant therapy in organ transplants.....	315
Role of immunological biomarkers in monitoring grafted patients .....	316
Improved matching of blood transfusion .....	317
<b>Personalized approaches to addiction.....</b>	<b>317</b>
Reversal of cocaine-evoked synaptic plasticity .....	317
Pharmacogenetics of drug addiction .....	318
Genetic polymorphism and management of alcoholism .....	318
Personalized therapy for smoking cessation.....	319
<i>Antidepressant therapy for smoking cessation .....</i>	<i>320</i>
<i>Effectiveness of nicotine patches in relation to genotype .....</i>	<i>320</i>
<b>Personalized geriatrics .....</b>	<b>320</b>
Chronological vs biological age .....	320
Pharmacogenetics and adverse drug reactions.....	321
<b>Personalized pediatrics.....</b>	<b>321</b>
WGS for personalized management of genetic disorders in critically ill infants.....	321
<b>Personalized nephrology.....</b>	<b>321</b>
Personalized management of chronic kidney disease .....	321
<i>Genes and chronic kidney disease .....</i>	<i>321</i>
<i>MicroRNAs and chronic kidney disease.....</i>	<i>322</i>
<i>Metabolomics and chronic kidney disease.....</i>	<i>322</i>
<i>TGF-<math>\beta</math>1 as a target for therapy of chronic kidney disease .....</i>	<i>322</i>
<i>Proteomics and chronic kidney disease .....</i>	<i>323</i>
Personalized management of renal disease associated with hypertension.....	323
<i>ACE inhibitors as renoprotective agents in hypertension.....</i>	<i>323</i>
<i>Gene associated with end-stage renal disease and hypertension .....</i>	<i>323</i>
Personalized approach to type I primary hyperoxaluria .....	324
<b>Personalized approaches to miscellaneous problems .....</b>	<b>324</b>
Female sexual dysfunction .....	324
<i>Hormone replacement therapy in women .....</i>	<i>324</i>
Personalized treatment of malaria.....	325
Personalized management of osteoporosis .....	325
Personalized care of trauma patients .....	326
Personalized medical care of astronauts during space flights .....	326
Personalized management of motion sickness.....	327
Personalized treatment of rare diseases.....	327
<b>Personalized preventive medicine .....</b>	<b>328</b>
<b>10. Personalized Therapy of Cancer .....</b>	<b>329</b>
<b>Introduction .....</b>	<b>329</b>
Challenges of cancer classification.....	329
Molecular biology of cancer as basis for personalized management .....	330
<i>Cancer epigenetics/epigenomics and personalized therapy .....</i>	<i>331</i>
<i>Cell division and mitotic spindles.....</i>	<i>331</i>
<i>Chromosomes and cancer .....</i>	<i>331</i>
<i>Chromosomal instability.....</i>	<i>332</i>
<i>DNA damage, repair and cancer.....</i>	<i>332</i>
<i>Gene mutations and cancer.....</i>	<i>333</i>
<i>Telomeres and cancer.....</i>	<i>334</i>
Systems biology of cancer.....	334
Relationships of technologies for personalized management of cancer .....	334
<b>Impact of molecular diagnostics on the management of cancer .....</b>	<b>335</b>
A universal NGS-based oncology test system .....	336
Analysis of RNA splicing events in cancer .....	336

Analysis of chromosomal alterations in cancer cells .....	337
Cancer classification using microarrays .....	337
Cancer gene panel for detection of genetic alterations .....	338
Companion diagnostics for cancer .....	338
Detection of loss of heterozygosity .....	338
Diagnostics for detection of minimal residual disease .....	339
DNA repair biomarkers .....	339
Fluorescent in situ hybridization .....	339
Gene expression profiling .....	340
<i>Gene expression profiles predict chromosomal instability in tumors</i> .....	341
<i>OnkoMatch tumor genotyping</i> .....	341
<i>Synthetic dosage lethality predicts tumor growth and patient survival</i> .....	341
GPS Cancer test .....	342
Isolation and characterization of circulating tumor cells .....	342
Modulation of CYP450 activity for cancer therapy .....	342
NanoFlares for detection of CTCs .....	343
Pathway-based analysis of cancer .....	343
<i>Conversion of gene-level information into pathway-level information</i> .....	343
<i>Personalized therapies based on oncogenic pathways signatures</i> .....	343
Quantum dot-based test for DNA methylation .....	344
Role of molecular imaging in personalized therapy of cancer .....	344
<i>Functional diffusion MRI</i> .....	345
<i>FDG-PET/CT for personalizing cancer treatment</i> .....	345
<i>Image-guided personalized drug delivery in cancer</i> .....	346
<i>Optoacoustic imaging and nanoparticles in cancer management</i> .....	346
<i>Tumor imaging and elimination by targeted gallium corrole</i> .....	346
<i>Future prospects of molecular imaging in management of cancer</i> .....	347
Unraveling the genetic code of cancer .....	347
<b>Cancer prognosis .....</b>	<b>347</b>
<b>Personalized cancer prevention .....</b>	<b>348</b>
Detection of mutations for cancer risk assessment and prevention .....	349
<b>Impact of biomarkers on management of cancer .....</b>	<b>349</b>
HER-2/neu oncogene as a biomarker for cancer .....	349
L-asparaginase treatment of cancer guided by a biomarker .....	350
Oncogene GOLPH3 as a cancer biomarker .....	350
Predictive biomarkers for cancer .....	350
Sequencing to discover biomarkers to personalize cancer treatment .....	351
VeraTag™ assay system for cancer biomarkers .....	351
<b>Determination of response to therapy .....</b>	<b>352</b>
Biomarker-based assays for predicting response to anticancer therapeutics .....	352
Ex vivo testing of tumor biopsy for chemotherapy sensitivity .....	352
Genomic approaches to predict response to anticancer agents .....	353
<i>Gene expression patterns to predict response of cancer to therapy</i> .....	353
<i>Genomic analysis of tumor biopsies</i> .....	353
<i>Genotype-dependent efficacy of pathway inhibition in cancer</i> .....	354
<i>Mutation detection at molecular level</i> .....	354
<i>RNA Disruption Assay™</i> .....	354
<i>Role of genetic variations in susceptibility to anticancer drugs</i> .....	354
Non-genetic factors for variations in response of cancer cells to drugs .....	355
Proteomic analysis of tumor biopsies to predict response to treatment .....	355
Real-time apoptosis monitoring .....	355
Serum nucleosomes as indicators of sensitivity to chemotherapy .....	356
Targeted microbubbles to tumors for monitoring anticancer therapy .....	356
PET imaging for determining response to chemotherapy .....	357
<i>PET imaging with tyrosine kinase inhibitors</i> .....	357
Concluding remarks about predicting response to anticancer therapy .....	357
<b>Molecular diagnostics combined with cancer therapeutics .....</b>	<b>358</b>
Aptamers for combined diagnosis and therapeutics of cancer .....	358
Combining diagnosis and therapy of metastatic cancer .....	359
Detection and destruction of CTCs with nanoparticles and X-rays .....	359
<b>Molecular profiling of cancer .....</b>	<b>360</b>
<b>Targeted cancer therapies .....</b>	<b>360</b>
Targeting glycoproteins on cell surface .....	360
Targeting pathways in cancer .....	360
Targeted personalized anticancer medicines in clinical use .....	361
<b>Immunotherapy of cancer .....</b>	<b>361</b>
Monoclonal antibodies for personalized management of cancer .....	361
Targeted MAb-based immune therapy of cancer .....	363
<i>MAbs targeted to alpha fetoprotein receptor</i> .....	363
<i>MAbs targeted to tumor blood vessels</i> .....	363
<i>MAbs that selectively target cancer</i> .....	363

<i>Velociximab</i> .....	364
MAbs for immune activation .....	364
Functional MAb-based therapies.....	364
Immunotherapy of dormant cancer .....	365
Combined use of MAbs and cytokines .....	366
Combining diagnostics with therapeutics based on MAbs.....	366
<i>Radiolabeled antibodies for detection and targeted therapy of cancer</i> .....	366
Cancer immunotherapy based on suppression of enzymes .....	368
<b>Personalized cancer vaccines.....</b>	<b>368</b>
Antigen-specific vaccines .....	368
<i>Active immunotherapy based on antigen specific to the tumor</i> .....	368
Tumor-derived vaccines.....	369
<i>FANG vaccine</i> .....	370
<i>MyVax</i> .....	370
<i>OncoVAX</i> .....	371
<i>Tumor cells treated with dinitrophenyl</i> .....	371
<i>Prophage</i> .....	371
<i>Melacine</i> .....	371
Patient-specific cell-based vaccines .....	372
<i>Dendritic cell-based vaccines</i> .....	372
Adoptive cell therapy .....	374
<i>Combination of antiangiogenic agents with ACT</i> .....	375
<i>Genetically targeted T cells for treating B cell malignancies</i> .....	375
<i>Genetic engineering of tumor cells</i> .....	376
<i>Hybrid cell vaccination</i> .....	376
Personalized peptide cancer vaccines.....	376
Targeting core mutations in cancer .....	377
Current status and future prospects of personalized cancer vaccines .....	377
<b>Personalized radiation therapy .....</b>	<b>378</b>
Peptide receptor radionuclide therapy.....	379
Use of radiation sensitivity biomarkers to personalized radiotherapy .....	380
Use of imaging to monitor radioimmunotherapy of non-Hodgkin lymphoma.....	380
<b>Role of nanobiotechnology in personalized management of cancer .....</b>	<b>381</b>
<b>Design of future personalized cancer therapies .....</b>	<b>381</b>
Personalized therapy of cancer based on cancer stem cells.....	382
Role of CRISPR-Cas9 in personalized cancer gene therapy .....	382
Role of epigenetics in development of personalized cancer therapies .....	383
<i>Cancer epigenetics and immunotherapy</i> .....	383
Selective destruction of cancer cells while sparing normal cells .....	384
<i>Sphingolipids</i> .....	384
<i>Hyperbaric oxygen as adjunct to radiotherapy</i> .....	384
<i>Targeting response to transformation-induced oxidative stress</i> .....	385
<i>Targeting enzymes to prevent proliferation of cancer cells</i> .....	385
Tissue systems biology approach to personalized management of cancer.....	385
<b>Role of oncoproteomics in personalized therapy of cancer .....</b>	<b>385</b>
Cancer tissue proteomics .....	386
Proteomics technologies to guide targeted drug selection for cancer .....	386
<i>LC-MS/MS proteomics as a companion diagnostic</i> .....	386
<i>Personalized cancer therapy based on targeted proteomics</i> .....	387
<b>Role of sequencing in personalized therapy of cancer .....</b>	<b>388</b>
<b>Pharmacogenomic-based chemotherapy .....</b>	<b>389</b>
Whole genome technology to predict drug resistance .....	389
Anticancer drug selection based on molecular characteristics of tumor.....	390
Testing microsatellite-instability for response to chemotherapy.....	390
<b>Pharmacogenetics of cancer chemotherapy .....</b>	<b>391</b>
CYP 1A2 .....	391
Thiopurine methyltransferase .....	391
Dihydropyrimidine dehydrogenase .....	392
UGT1A1 test as guide to irinotecan therapy .....	392
<b>Role of computational models in personalized anticancer therapy.....</b>	<b>393</b>
A computational model of kinetically tailored treatment .....	393
Mathematical modeling of tumor microenvironments.....	394
Modeling signaling pathways to reposition anticancer drugs .....	394
<b>Therapy resistance in cancer .....</b>	<b>394</b>
Mechanism of therapy resistance in cancer.....	395
<i>Cancer stem cells and radioresistance</i> .....	395
<i>Expression of P-glycoprotein gene by tumor</i> .....	395
<i>Overexpression of multidrug resistance gene</i> .....	395
<i>P53 mutations</i> .....	396
<i>Role of splice variants in resistance to cancer therapy</i> .....	396
Detection of drug resistance.....	396

<i>Anaplastic lymphoma kinase</i> .....	396
<i>CRISPR for studying mechanism of drug-resistance in cancer</i> .....	396
<i>Metabolic profiling of cancer</i> .....	397
Management of drug resistance in cancer.....	397
<i>Chemogenomic approach to drug resistance</i> .....	397
<i>Determination of chemotherapy response by topoisomerase levels</i> .....	398
<i>Management of drug resistance in leukemia</i> .....	398
<i>Patient-derived xenograft mouse models in drug resistant cancer</i> .....	399
<i>Resistance to vaccines in cancer recurrence after surgery</i> .....	399
<i>Systems biology approach to drug-resistant cancer</i> .....	399
<b>Personalized therapy of cancer metastases.....</b>	<b>400</b>
Technologies for analysis of CTCs.....	400
<i>Microfluidic technologies</i> .....	400
<i>BEAMing technology for analysis of circulating tumor DNA</i> .....	401
<i>Technologies for detection of interplay of environments and CTCs</i> .....	401
Systemic antitumor effect of localized radiotherapy for cancer metastases.....	402
Diagnosis of cancer of an unknown primary.....	402
<b>Personalized management of cancers of various organs.....</b>	<b>403</b>
Personalized management of bladder tumors.....	403
Personalized management of brain tumors.....	403
<i>Aptamers for selective targeting of tumor initiating cells in GBM</i> .....	403
<i>Bioinformatic approach to personalizing treatment of GBM</i> .....	404
<i>Biosimulation approach to personalizing treatment of brain cancer</i> .....	404
<i>Brain cancer chip for personalized drug screening</i> .....	404
<i>Combination of gene therapy and CAR-T cell therapy for GBM</i> .....	405
<i>Drug resistance in GBM</i> .....	405
<i>Genetics and genomics of GBM</i> .....	406
<i>Genomic analysis as a guide to personalized therapy of GBM</i> .....	407
<i>Induced neural stem cells for personalized therapy of GBM</i> .....	408
<i>Molecular diagnostics for personalized management of GBM</i> .....	408
<i>Personalized vaccine for GBM</i> .....	410
<i>Personalized chemotherapy of GBM</i> .....	411
<i>Personalized therapy of oligodendroglial tumors</i> .....	412
<i>Personalized therapy of neuroblastomas</i> .....	412
<i>Personalized therapy of medulloblastomas</i> .....	413
<i>Personalized management of germ cell brain tumors</i> .....	414
<i>Personalized management of meningiomas</i> .....	414
<i>Supratentorial hemispheric diffuse low-grade gliomas</i> .....	414
<i>Targeted therapy of BRAF V600E mutant papillary craniopharyngioma</i> .....	415
<i>Future prospects of personalized therapy of malignant brain tumors</i> .....	415
Personalized management of breast cancer.....	415
<i>Biomarker-guided decisions for breast cancer therapy</i> .....	416
<i>Developing personalized drugs for breast cancer</i> .....	416
<i>Gene expression plus conventional predictors of breast cancer</i> .....	417
<i>Her2 testing in breast cancer as a guide to treatment</i> .....	418
<i>HER2/neu-derived peptide vaccine for breast cancer</i> .....	419
<i>Trends in treatment patterns and outcomes for DCIS</i> .....	420
<i>Molecular diagnostics in breast cancer</i> .....	420
<i>Molecular classification of infiltrating breast cancer</i> .....	423
<i>Monitoring of circulating tumor cells in breast cancer</i> .....	423
<i>Pharmacogenetics of breast cancer</i> .....	424
<i>Proteomics-based personalized management of breast cancer</i> .....	424
<i>Predicting response to chemotherapy in breast cancer</i> .....	425
<i>Prediction of resistance to chemotherapy in breast cancer</i> .....	428
<i>Prediction of adverse reaction to radiotherapy in breast cancer</i> .....	429
<i>Prediction of recurrence in breast cancer for personalizing therapy</i> .....	429
<i>Prognostic tests for breast cancer</i> .....	431
<i>Racial factors in the management of breast cancer</i> .....	433
<i>RATHER consortium to study personalized approach to breast cancer</i> .....	433
<i>Ribociclib as first-line therapy for HR-positive breast cancer</i> .....	434
<i>TAILORx (Trial Assigning Individualized Options for Treatment)</i> .....	434
<i>Tamoxin therapy for ER-positive breast cancer</i> .....	434
<i>Triple negative breast cancer</i> .....	435
<i>Current trends and future of breast cancer research</i> .....	436
<i>Understanding tumor diversity in mouse mammary cancer model</i> .....	437
Personalized management of ovarian cancer.....	437
<i>Early diagnosis of ovarian cancer</i> .....	437
<i>Determining response to chemotherapy in ovarian cancer</i> .....	438
<i>Prognosis of ovarian cancer based on CLOVAR</i> .....	439
<i>Recurrent and drug-resistant ovarian cancer</i> .....	439
<i>Pathway targeted therapies for ovarian cancer</i> .....	440

<i>Repurposing auranofin for treatment of ovarian cancer</i> .....	442
<i>Targeting hematogenous metastasis of ovarian cancer</i> .....	442
<i>Vynfinit® for platinum-resistant ovarian cancer</i> .....	442
Personalized management of head and neck cancer .....	443
<i>Molecular characterization of head and neck cancer using omics</i> .....	443
<i>Relevance of biomarkers of HPV-related head and neck cancer</i> .....	443
<i>Molecular targeted therapies for HNSCC</i> .....	444
Personalized management of hematological malignancies .....	444
<i>Personalized management of acute lymphoblastic leukemia</i> .....	445
<i>Personalized management of chronic lymphocytic leukemia</i> .....	446
<i>Personalized management of acute myeloid leukemia</i> .....	448
<i>Personalized management of chronic myeloid leukemia</i> .....	449
<i>Personalized management of multiple myeloma</i> .....	450
<i>Personalized management of myelodysplastic syndrome</i> .....	451
Personalized management of lymphomas.....	452
<i>Personalized management B cell lymphomas</i> .....	452
<i>Personalized vaccine for follicular lymphoma</i> .....	453
<i>Pharmacoproteomics approach to diffuse large B cell lymphoma</i> .....	453
<i>Companion diagnostic for treatment of lymphoma with Adcentris™</i> .....	454
Personalized management of gastrointestinal tumors .....	454
<i>Personalized management of esophageal cancer</i> .....	454
<i>Personalized management of gastric cancer</i> .....	455
<i>Personalized management of gastrointestinal stromal tumors</i> .....	456
Personalized management of colorectal cancer .....	456
<i>Developing personalized therapies for CRC</i> .....	456
<i>Molecular diagnosis for guiding personalized management of CRC</i> .....	457
<i>Role of staging of CRC in prognosis and management decisions</i> .....	458
<i>Role of biomarkers in personalized management of CRC</i> .....	459
<i>Role of miRNA modeling in personalized management of CRC</i> .....	460
<i>Resistance to targeted EGFR blockade in CRC</i> .....	460
<i>Sequencing for personalized management of colorectal cancer</i> .....	461
<i>Systems biology approach to drug resistance in colorectal cancer</i> .....	462
Personalized management of liver cancer.....	463
<i>Prognosis of HCC in relation to management</i> .....	463
<i>Prediction of recurrence of hepatocellular carcinoma</i> .....	464
<i>Prediction of survival of patients with fibrolamellar HCC</i> .....	464
Personalized management of lung cancer.....	464
<i>ALK inhibitors for personalized management of NSCLC</i> .....	464
<i>Bronchial genomic classifier for diagnostic of lung cancer</i> .....	465
<i>Copy number variations as a diagnostic tool for lung cancer</i> .....	465
<i>EGFR tyrosine kinase inhibitor treatment</i> .....	466
<i>Development of resistance to EGFR inhibitors</i> .....	468
<i>Molecular subtyping of lung cancer</i> .....	468
<i>miRNA classifiers as diagnostic/prognostic tools in lung cancer</i> .....	469
<i>Personalized therapy of NSCLC based on KIF5B/RET fusion oncogene</i> .....	469
<i>Predicting response of NSCLC to platinum-based therapy</i> .....	469
<i>Proteomics for discovery of metabolic biomarkers of lung cancer</i> .....	469
<i>Role of a new classification system in the management of lung cancer</i> .....	470
<i>Selecting therapy of cancer arising from respiratory papillomatosis</i> .....	470
<i>Sequencing the genomes of SCLC</i> .....	470
<i>Testing for response to chemotherapy in lung cancer</i> .....	471
<i>Testing for prognosis of lung cancer</i> .....	471
<i>Testing for recurrence of lung cancer</i> .....	472
Personalized management of malignant melanoma .....	472
<i>Inhibitors of BRAF mutation for metastatic melanoma</i> .....	473
<i>Management of drug-resistant metastatic melanoma</i> .....	473
<i>Vaccine for malignant melanoma based on heat shock protein</i> .....	474
Personalized management of endocrine tumors .....	474
<i>Adosterone producing tumors</i> .....	474
<i>Neuroendocrine tumors</i> .....	474
<i>Parathyroid tumors</i> .....	475
<i>Personalized management of pheochromocytoma and paraganglioma</i> .....	476
Personalized management of osteosarcoma .....	476
Personalized management of pancreatic cancer .....	477
<i>Biomarkers of pancreatic cancer</i> .....	478
<i>Histone modifications predict treatment response in pancreatic cancer</i> .....	478
<i>Transport properties of pancreatic cancer and gemcitabine delivery</i> .....	478
Personalized management of prostate cancer .....	479
<i>Assessing susceptibility to prostate cancer by genotyping</i> .....	479
<i>Diagnostics for guiding therapy of prostate cancer</i> .....	480
<i>Detection of prostate cancer metastases</i> .....	480

<i>Early detection of cancer recurrence and guiding treatment</i> .....	481
<i>Effects of lifestyle changes shown by gene expression studies</i> .....	481
<i>Epigenetics-based assays for guiding decision to biopsy prostate</i> .....	482
<i>Genomic patterns of aggressiveness of prostate cancer</i> .....	482
<i>Personalized peptide vaccine for prostate cancer</i> .....	482
<i>Selection of prostate cancer patients responsive to rucaparib therapy</i> .....	483
Personalized management of thyroid cancer .....	483
<b>Future of cancer therapy</b> .....	<b>483</b>
Challenges for developing personalized cancer therapies.....	484
Cancer Genome Atlas .....	484
Cancer Moonshot .....	485
<i>Blood Profiling Atlas</i> .....	485
<i>NCI collaborations</i> .....	485
COLTHERES consortium .....	486
Computer and imaging technologies for personalizing cancer treatment.....	486
Genomic Cancer Care Alliance .....	487
Integrated genome-wide analysis of cancer for personalized therapy .....	487
International Cancer Genome Consortium .....	487
National Cancer Institute of US.....	489
<i>Catalog of cancer genes for personalized therapy</i> .....	489
<i>NCI-designated Comprehensive Cancer Centers</i> .....	490
<i>Role of NCI Genomic Data Commons in personalized cancer therapy</i> .....	490
PREDICT Consortium .....	491
Quebec Clinical Research Organization in Cancer .....	491
The San Antonio 1000 Cancer Genomes Project.....	491
<b>Companies involved in developing personalized oncology</b> .....	<b>492</b>

## **11. Development of Personalized Medicine ..... 497**

<b>Introduction</b> .....	<b>497</b>
<b>Non-genomic factors in the development of personalized medicine</b> .....	<b>497</b>
Personalized medicine based on circadian rhythms.....	497
Cytomics as a basis for personalized medicine .....	499
Intestinal microflora .....	499
<i>Gut microbiome compared to human genome</i> .....	499
<i>Metabolic interactions of the host and the intestinal microflora</i> .....	500
Role of drug delivery in personalized medicine.....	500
Personalized approach to clinical trials .....	500
<i>Adaptive clinical trials</i> .....	501
<i>Bayesian approach in biomarker-based clinical trials</i> .....	502
<i>Clinical trials of therapeutics and companion diagnostics</i> .....	503
<i>Clinical trials on selected subpopulations of patients</i> .....	503
<i>Clinical trials networks</i> .....	503
<i>Creative clinical trial design</i> .....	504
<i>Individualizing risks and benefits in clinical trials</i> .....	504
<b>Players in the development of personalized medicine</b> .....	<b>505</b>
Personalized Medicine Coalition.....	505
Role of pharmaceutical industry .....	506
<i>Repositioning of drugs for personalized medicine</i> .....	507
<i>Discovery of personalized medicines</i> .....	507
<i>Production and distribution of personalized medicines</i> .....	507
Role of biotechnology companies .....	508
Role of life sciences industries .....	508
Role of biomedical engineering in wearable devices for personalized healthcare .....	509
Role of molecular imaging in personalized medicine .....	509
<i>Molecular imaging for personalized drug development in oncology</i> .....	510
<i>Molecular imaging and CNS drug development</i> .....	511
<i>Companies involved in molecular imaging</i> .....	512
Role of the clinical laboratories .....	513
Role of the US government in personalized medicine .....	513
<i>Precision Medicine Initiative</i> .....	514
<i>Department of Health and Human Services and personalized medicine</i> .....	516
<i>Agency for Healthcare Research and Quality</i> .....	517
<i>Comparative effectiveness research</i> .....	518
Role of the US Government agencies in personalized medicine .....	519
<i>NIH's Roadmap Initiative for Medical Research</i> .....	520
<i>NIH and personalized medicine</i> .....	520
<i>NIH collaboration with the FDA</i> .....	520
<i>NIH and Genetic Testing Registry</i> .....	521
<i>National Human Genome Research Institute</i> .....	521
<i>National Institute of General Medical Sciences</i> .....	521
<i>National Institute of Standards and Technology</i> .....	523



<i>Role of the Centers for Disease Control</i> .....	524
Role of academic institutions and health centers in the US .....	524
<i>Baylor College of Medicine</i> .....	524
<i>California Initiative to Advance Precision Medicine</i> .....	525
<i>Children's Hospital of Los Angeles</i> .....	525
<i>Clinical Proteomics Program of NCI &amp; FDA</i> .....	525
<i>Coriell Personalized Medicine Collaborative™</i> .....	526
<i>Delaware Valley Personalized Medicine Project</i> .....	526
<i>Duke University Medical Center and genomic medicine</i> .....	526
<i>Evaluation of genetic tests and genomic applications</i> .....	527
<i>Indiana University Institute for Personalized Medicine</i> .....	528
<i>Inova Center for Personalized Health</i> .....	528
<i>Institute of Medicine's role in personalized medicine</i> .....	528
<i>Jackson Laboratory for Genomic Medicine</i> .....	529
<i>Johns Hopkins Center for Personalized Cancer Medicine Research</i> .....	529
<i>Mayo Clinic's Centers for Individualized Medicine</i> .....	530
<i>Mt. Sinai Medical Center's Personalized Medicine Research Program</i> .....	530
<i>North Shore University's Center for Personalized Medicine</i> .....	531
<i>P4 Medicine Institute</i> .....	531
<i>Personalized Medicine Partnership of Florida</i> .....	532
<i>Personalized oncology at Massachusetts General Hospital</i> .....	532
<i>Personalized oncology at Oregon Health &amp; Science University</i> .....	532
<i>Pharmacogenetics Research Network and Knowledge Base</i> .....	533
<i>Southeast Nebraska Cancer Center's Personalized Medicine Network</i> .....	533
<i>Spectrum Health Center for personalized cancer care</i> .....	533
<i>Stanford Center for Genomics and Personalized Medicine</i> .....	534
<i>UAB-HudsonAlpha Center for Genomic Medicine</i> .....	534
<i>University of Colorado's Center for Personalized Medicine</i> .....	534
<i>UNC Institute for Pharmacogenomics and Individualized Therapy</i> .....	535
<i>Weill Cornell's Englander Institute for Precision Medicine</i> .....	535
<i>Wisconsin Genomics Initiative</i> .....	536
Role of academic collaborations with companies .....	536
<i>New York Genome Center</i> .....	536
Role of healthcare organizations .....	536
Role of the medical profession .....	537
<i>The American Medical Association and personalized medicine</i> .....	537
<i>Education of the physicians</i> .....	537
<i>Off-label prescribing and personalized medicine</i> .....	538
<i>Medical education</i> .....	538
Role of patients .....	538
<i>Public attitude towards personalized medicine</i> .....	539
<i>Patient participation in disease management decisions</i> .....	540
<b>Role of genetic banking systems and databases .....</b>	<b>540</b>
Role of biobanks in development of personalized medicine .....	540
UK Biobank .....	541
Biobanking and development of personalized medicine in EU.....	541
<i>BBMRI-ERIC</i> .....	541
CARTaGENE for biobanks in Canada .....	542
Personalized medicine based on PhysioGenomics™ technology .....	542
<b>Role of bioinformatics in development of personalized medicine.....</b>	<b>543</b>
Biosensing and wearable devices for monitoring of health .....	544
Biosimulation techniques for developing personalized medicine.....	544
Genomic data analysis.....	545
Exploration of disease-gene relationship .....	545
Health information management.....	545
Electronic health records.....	545
<i>Cost of EHR and savings on healthcare expenses in the US</i> .....	546
<i>EHRs and genome-wide studies</i> .....	547
<i>Linking patient medical records and genetic information</i> .....	547
<i>Management of personal genomic data</i> .....	547
<i>Use of EHRs for improving safety of new medicines</i> .....	548
<i>Use of EHRs for genetic research</i> .....	548
<i>Use of EHRs for personalized drug discovery and development</i> .....	549
Personalized prognosis of disease .....	549
<b>Integration of technologies for personalized medicine .....</b>	<b>549</b>
<b>Global scope of personalized medicine .....</b>	<b>550</b>
<i>Global Alliance for Genomics and Health</i> .....	550
Personalized medicine in Canada .....	550
<i>Personalized medicine at Ontario Institute for Cancer Research</i> .....	550
<i>Personalized Medicine Partnership for Cancer in Quebec</i> .....	552
<i>Quebec Center of Excellence in Personalized Medicine</i> .....	553

Personalized medicine in the EU.....	553
<i>European Personalized Medicine Diagnostics Association</i> .....	553
<i>UK National Health Service and medical genetics</i> .....	554
<i>UK's Precision Medicine Catapult</i> .....	554
<i>Personalized medicine in Germany</i> .....	555
Personalized medicine in Israel .....	555
Personalized medicine in Japan .....	556
Personalized medicine in the developing countries .....	556
<i>Personalized medicine in the Middle East</i> .....	557
<i>Personalized medicine in China</i> .....	557
<b>Advantages of personalized medicine .....</b>	<b>558</b>
<b>Limitations of personalized medicine .....</b>	<b>558</b>
Non-genomic factors in response to drugs.....	559
Incidental findings in genetic screening and clinical sequencing .....	559
<b>Future of personalized medicine .....</b>	<b>561</b>
Ongoing genomic projects.....	561
<i>Understanding the genetic basis of diseases</i> .....	561
<i>Personal Genome Project</i> .....	561
<i>Genome-wide association studies</i> .....	562
<i>The 1000 Genomes Project</i> .....	563
<i>Genomics of aging in a genetically homogeneous population</i> .....	563
Translational science and personalized medicine .....	564
<i>Translation of genomic research into genetic testing for healthcare</i> .....	564
<i>Long-term behavioral effects of personal genetic testing</i> .....	565
Personalized predictive medicine.....	565
Connected health and personalized medicine .....	566
Opportunities and challenges.....	566
<i>Comparative-effectiveness research and personalized medicine</i> .....	566
<i>Genetic testing and concerns about equality of healthcare</i> .....	566
<i>Initiative for delivery for precision medicine</i> .....	567
<i>IGNITE network – implementing personalized medicine in clinical care</i> .....	567
<i>Prospects and limitations of genetic testing</i> .....	568
<i>Personalized medicine and public health</i> .....	569
<i>Pharmacotyping</i> .....	569
<i>Medicine in the year 2021</i> .....	570
Concluding remarks about the future of personalized medicine .....	570

## **12. Ethical, Legal and Regulatory Aspects of Personalized Medicine. 573**

<b>Introduction to ethical issues .....</b>	<b>573</b>
Ethical issues of pharmacogenetics .....	573
Ethical aspects of genetic information.....	573
<i>Ethical issues of whole genome analysis</i> .....	573
<i>Ethical aspects of direct-to-consumer genetic services</i> .....	574
<i>Privacy issues in personalized medicine</i> .....	575
<i>Genetic Information Nondiscrimination Act in the US</i> .....	576
<i>UNESCO and ethical aspects of personalized medicine</i> .....	576
Genotype-specific clinical trials .....	576
Social issues in personalized medicine .....	577
<i>Race and personalized medicine</i> .....	577
<b>Legal issues of personalized medicine .....</b>	<b>579</b>
Gene patents and personalized medicine.....	580
<b>Regulatory aspects .....</b>	<b>580</b>
FDA and personalized medicine.....	581
<i>FDA oversight of NGS for personalized medicine</i> .....	581
FDA and molecular diagnostics in relation to personalized medicine.....	582
<i>CLSI guideline for the use of RNA controls in gene expression assays</i> .....	582
<i>Evaluation of companion diagnostics/therapeutic</i> .....	583
<i>FDA oversight of laboratory developed tests</i> .....	584
<i>FDA regulation of multivariate index assays</i> .....	585
<i>IVD device and drug co-development</i> .....	586
Regulatory aspects of pharmacogenetics.....	587
Regulation of direct-to-consumer genetic testing .....	587
<i>Need for regulatory oversight of DTC</i> .....	588
FDA and pharmacogenomics .....	590
<i>FDA guidance for pharmacogenomic data submissions</i> .....	591
<i>Joint guidelines of the FDA and EU regulators for pharmacogenomics</i> .....	592
<i>Pharmacogenomic/pharmacogenetic information in drug labels</i> .....	592
<i>FDA guidelines for pharmacogenomics-based dosing</i> .....	593
<i>FDA and validation of biomarkers</i> .....	593
FDA and predictive medicine .....	594

<b>13. Commercial Aspects of Personalized Medicine .....</b>	<b>595</b>
<b>Introduction .....</b>	<b>595</b>
Perceived financial concerns .....	595
Personalized medicine and orphan drug syndrome .....	595
<b>Commercial aspects of pharmacogenomics.....</b>	<b>595</b>
Cost of DNA testing .....	595
Cost of sequencing the human genome .....	596
Cost of genotyping .....	598
Cost of pharmacogenomics-based clinical trials.....	599
Business development of pharmacogenomic companies.....	599
<b>Cost of personalized healthcare .....</b>	<b>599</b>
The rising healthcare costs in the US.....	599
<i>Genetic testing and cost of healthcare .....</i>	<i>600</i>
Reducing healthcare costs by combining diagnostics with therapeutics .....	601
<i>Cost-effectiveness of pharmacogenetic testing.....</i>	<i>601</i>
<i>Cost-effectiveness of CYP genotyping-based pharmacotherapy .....</i>	<i>602</i>
<i>Cost effectiveness of HIV genotyping in treatment of AIDS.....</i>	<i>602</i>
<i>Cost-effectiveness of warfarin pharmacogenomics.....</i>	<i>603</i>
<i>Cost-benefit analysis of KRAS and BRAF screening in CRC.....</i>	<i>603</i>
<i>Lowering the high costs of cancer chemotherapy .....</i>	<i>603</i>
Overall impact of personalized medicine on healthcare .....	604
<b>Drivers for the development of personalized medicine .....</b>	<b>604</b>
Evolution of medicine as a driver for personalized therapy markets .....	605
<b>Collaboration between the industry and the academia .....</b>	<b>605</b>
<b>Personalized medicine and drug markets .....</b>	<b>606</b>
Segmentation of therapeutic drug markets.....	606
Reasons for increase of market values of personalized medicines.....	606
Growth of markets relevant to personalized medicine .....	607
<i>Biochips for diagnosis .....</i>	<i>607</i>
<i>Pharmacogenetics .....</i>	<i>608</i>
<i>Pharmacogenomics .....</i>	<i>608</i>
<i>Pharmacoproteomics .....</i>	<i>608</i>
<i>Point-of-Care.....</i>	<i>608</i>
<i>SNP market.....</i>	<i>608</i>
Markets for personalized medicines according to therapeutic areas .....	608
<i>Market for personalized cancer therapy.....</i>	<i>609</i>
Markets for personalized medicines according to geographical regions.....	609
Market opportunities for personalization of medicine .....	609
Impact of personalized medicine on other industries.....	610
Strategies for developing and marketing personalized medicine .....	611
<i>Education of the public .....</i>	<i>611</i>
<i>Role of the Internet in development of personalized medicine.....</i>	<i>612</i>
<i>Marketing companion diagnostics for personalized medicine .....</i>	<i>612</i>
<b>14. References.....</b>	<b>615</b>

## Tables

Table 1-1: Selected terms relevant to the concept of personalized medicine.....	27
Table 1-2: Landmarks in the historical development of personalized medicine .....	28
Table 1-3: Genetic variations in the human genome.....	34
Table 1-4: Examples of systems medicine-based diagnostic/therapeutic approaches .....	51
Table 2-1: Molecular diagnostic technologies used for personalized medicine .....	57
Table 2-2: Applications of biochip technology relevant to personalized medicine .....	79
Table 2-3: Companies developing haplotyping technology .....	94
Table 2-4: Technologies for SNP analysis.....	94
Table 2-5: A sampling of companies involved in technologies for SNP genotyping .....	100
Table 2-6: Comparison of proteomic and genomic approaches in personalized medicine .....	106
Table 2-7: Selected methods for gene expression profiling.....	112
Table 2-8: A selection of companies with gene expression technologies .....	117
Table 2-9: Drugs requiring biomarker/companion diagnostic information in the label .....	119
Table 2-10: Companies involved in companion diagnostics.....	120
Table 2-11: Applications of point-of-care diagnosis .....	122
Table 2-12: Companies developing point-of-care diagnostic tests .....	123
Table 2-13: Companies offering genetic screening tests directly to consumers .....	127
Table 3-1: Pharmacogenetic vs. pharmacogenomic studies .....	134
Table 3-2: Enzymes relevant to drug metabolism .....	136
Table 3-3: Examples of mutation of the enzyme CYP450 .....	137

Table 3-4: Frequency distribution of drugs metabolized by major isoforms of CYP450. ....	137
Table 3-5: Commonly prescribed medications, which are metabolized by CYP2D6.....	137
Table 3-6: Polymorphisms in drug target genes that can influence drug response.....	143
Table 3-7: Effect of genetic polymorphisms on disease response to drugs.....	144
Table 3-8: Examples of genetically determined adverse reactions to drugs .....	147
Table 3-9: Examples of genotyping and phenotyping in some diseases.....	155
Table 3-10: Companies with novel molecular toxicology technology.....	158
Table 3-11: Pharmacogenomic biomarkers in drug labeling.....	161
Table 4-1: Role of pharmacogenomics in variable therapy targets.....	169
Table 4-2: Role of pharmacogenomics in clinical trials .....	172
Table 4-3: Examples of pharmacogenomics-based clinical studies.....	173
Table 4-4: Tumor suppressor genes, their chromosomal location, function and associated tumors. ....	176
Table 4-5: Gene polymorphisms relevant to cardiovascular disease management.....	177
Table 4-6: Companies involved in cardiovascular genomics.....	179
Table 4-7: A sampling of companies involved in neuropharmacogenomics .....	181
Table 8-1: Companies involved in personalized nutrition.....	210
Table 9-1: Important therapeutic areas for personalized medicine .....	213
Table 9-2: Enzymes that metabolize antipsychotics.....	228
Table 9-3: Enzymes that metabolize antidepressants .....	230
Table 9-4: Biomarkers of response to antidepressant treatment .....	230
Table 9-5: Biomarkers of epilepsy.....	238
Table 9-6: Influence of gene polymorphisms on efficacy of antiepileptic drugs.....	242
Table 9-7: Role of cell therapy in management of stroke according to stage.....	252
Table 9-8: Gene expression as biomarker of response to IFN- $\beta$ in multiple sclerosis.....	256
Table 9-9: Biomarkers of traumatic brain injury.....	257
Table 9-10: P450 isoforms in the metabolism of drugs used in the management of pain.....	260
Table 9-11: Personalized management of neuropathic pain based on mechanism .....	263
Table 9-12: Genes that cause cardiovascular diseases.....	266
Table 9-13: Genetic influences on pharmacotherapy of alcoholism .....	319
Table 10-1: Factors that drive the development of personalized therapy in cancer .....	329
Table 10-2: Impact of molecular diagnostics on the management of cancer .....	335
Table 10-3: FDA-approved companion diagnostics for cancer .....	338
Table 10-4: Marketed anticancer personalized medicines .....	361
Table 10-5: Monoclonal antibodies for cancer approved by the FDA .....	362
Table 10-6: Clinical trials of personalized cancer vaccines.....	377
Table 10-7: Future developments in oncology relevant to personalized management .....	483
Table 10-8: Selected companies involved in developing personalized oncology .....	493
Table 11-1: Bayesian versus frequentist approaches in clinical trials .....	502
Table 11-2: Players in the development of personalized medicine .....	505
Table 11-3: Members of the Personalized Medicine Coalition .....	505
Table 11-4: Biobanks relevant to personalized medicine .....	541
Table 11-5: Role of bioinformatics in the development of personalized medicine.....	543
Table 11-6: Advantages of personalized medicine for the biopharmaceutical industry.....	558
Table 11-7: Advantages of personalized medicine for the patients .....	558
Table 11-8: Advantage of personalized medicine for the physicians.....	558
Table 11-9: Advantage of personalized medicine for the healthcare providers .....	558
Table 11-10: Limitations of personalized medicine .....	558
Table 11-11: Recommendations of the Association for Molecular Pathology on incidental findings .....	560
Table 11-12: Methods of translational science that are relevant to personalized medicine.....	564
Table 11-13: Companies involved in predictive healthcare .....	565
Table 11-14: Delivery for precision medicine.....	567
Table 12-1: Drugs with genetic information in their labels.....	592
Table 13-1: Drivers for the development of personalized medicine.....	604
Table 13-2: Growth of markets relevant to personalized medicine 2016-2026 .....	607
Table 13-3: Markets for personalized medicine according to therapeutic area 2016-2026.....	609
Table 13-4: Markets for personalized medicine in major regions 2016-2026.....	609
Table 13-5: Lack of efficacy in current therapy .....	610
Table 13-6: Impact of personalized medicine on other industries .....	610
Table 13-7: Strategies to develop personalized medicine .....	611
Table 13-8: Role of the Internet in development of personalized medicine .....	612

## Figures

Figure 1-1: Relation of personalized medicine to other technologies.....	44
Figure 1-2: Relation of systems pharmacology to personalized medicine.....	50
Figure 2-1: Role of sequencing in personalized medicine.....	75
Figure 2-2: Role of biochip/microarray technology in personalized medicine .....	79
Figure 2-3: Application of biochips/microarrays in personalized therapy.....	80
Figure 2-4: Affymetrix GeneChip technology .....	81
Figure 2-5: Role of CYP450 genotyping in development of personalized medicine .....	82

Figure 2-6: Role of SNPs in personalized medicine .....	90
Figure 2-7: A scheme of integrated healthcare and personalized medicine .....	129
Figure 3-1: Pharmacogenetics as a link between genotype and phenotype .....	133
Figure 3-2: Role of pharmacogenetic technologies in personalized medicine .....	134
Figure 4-1: Impact of new technologies at various stages of the drug discovery process.....	171
Figure 4-2: Steps in the application of pharmacogenomics in clinical trials .....	173
Figure 7-1: Role RNAi in development of personalized medicine.....	201
Figure 9-1: Workflow of genotypic resistance analysis for personalized HIV therapy .....	220
Figure 9-2: Components of multimodal therapy for neurological disorders.....	234
Figure 9-3: Scheme of iPSCs use for personalized cell therapy of Parkinson disease .....	237
Figure 9-4: An algorithm for personalized management of epilepsy .....	245
Figure 9-5: Algorithm for anticoagulant therapy to prevent stroke in atrial fibrillation.....	250
Figure 9-6: Spot sign of extravasation and expansion of intracerebral hematoma .....	251
Figure 9-7: A scheme of personalized therapy of multiple sclerosis .....	253
Figure 9-8: Essential components of personalized management of pain .....	258
Figure 9-9: Genetic and non-genetic factors affecting efficacy and side effects of opioids.....	261
Figure 9-10: An algorithm for personalized management of pain .....	263
Figure 9-11: Assessment of stable coronary artery disease .....	272
Figure 9-12: Flow chart of personalized approach to management of atrial fibrillation .....	277
Figure 9-13: A scheme of personalized approach to management of hypertension .....	285
Figure 9-14: Basis of personalized approach to idiopathic pulmonary fibrosis (IPF) .....	300
Figure 9-15: Steps in growing a new heart in vitro for transplantation.....	314
Figure 10-1: Relationships of technologies for personalized management of cancer.....	335
Figure 10-2: Integration of technologies for personalized prevention of cancer .....	348
Figure 10-3: CRISPR-Cas9 in personalized cancer gene therapy .....	382
Figure 10-4: Use of LC-MS/MS to select appropriate targeted therapy for cancer .....	386
Figure 10-5: Personalized cancer therapy based on targeted proteomics.....	388
Figure 10-6: Applications of NCI Genomic Data Commons .....	490
Figure 11-1: Integration of technologies for the development of personalized medicine .....	549
Figure 12-1: Strategy for drug and test co-development.....	586
Figure 13-1: Cost of sequencing per genome .....	598
Figure 13-2: Evolution of personalized medicine as a market driver .....	605